Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04476329
Title Optimization for Regorafenib in HCC (ReDos HCC)
Acronym ReDos HCC
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors SC Liver Research Consortium, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Banner MD Anderson Cancer Center Gilbert Arizona 85234 United States Details
VA Long Beach Health System Long Beach California 90822 United States Details
Tulane University New Orleans Louisiana 70112 United States Details
Henry Ford Health Systems Detroit Michigan 48202 United States Details
Cancer and Hematology Centers of Western Michigan Grand Rapids Michigan 49503 United States Details
Saint Louis University Saint Louis Missouri 63104 United States Details
Comprehensive Cancer Centers of Nevada Henderson Nevada 89014 United States Details
University of Cincinnati Medical Center Cincinnati Ohio 45219 United States Details
Albert Einstein Medical Center Philadelphia Pennsylvania 19141 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field